Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Prevention, Detection And Management Of Cancer Treatment-induced Cardiotoxicity: A Meta-review

A. Conway, A. McCarthy, P. Lawrence, R. Clark
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BackgroundThe benefits associated with some cancer treatments do not come without risk. A serious side effect of some common cancer treatments is cardiotoxicity. Increased recognition of the public health implications of cancer treatment-induced cardiotoxicity has resulted in a proliferation of systematic reviews in this field to guide practice. Quality appraisal of these reviews is likely to limit the influence of biased conclusions from systematic reviews that have used poor methodology related to clinical decision-making. The aim of this meta-review is to appraise and synthesise evidence from only high quality systematic reviews focused on the prevention, detection or management of cancer treatment-induced cardiotoxicity.MethodsUsing Cochrane methodology, we searched databases, citations and hand-searched bibliographies. Two reviewers independently appraised reviews and extracted findings. A total of 18 high quality systematic reviews were subsequently analysed, 67 % (n = 12) of these comprised meta-analyses.ResultsOne systematic review concluded that there is insufficient evidence regarding the utility of cardiac biomarkers for the detection of cardiotoxicity. The following strategies might reduce the risk of cardiotoxicity: 1) The concomitant administration of dexrazoxane with anthracylines; 2) The avoidance of anthracyclines where possible; 3) The continuous administration of anthracyclines (>6 h) rather than bolus dosing; and 4) The administration of anthracycline derivatives such as epirubicin or liposomal-encapsulated doxorubicin instead of doxorubicin. In terms of management, one review focused on medical interventions for treating anthracycline-induced cardiotoxicity during or after treatment of childhood cancer. Neither intervention (enalapril and phosphocreatine) was associated with statistically significant improvement in ejection fraction or mortality.ConclusionThis review highlights the lack of high level evidence to guide clinical decision-making with respect to the detection and management of cancer treatment-associated cardiotoxicity. There is more evidence with respect to the prevention of this adverse effect of cancer treatment. This evidence, however, only applies to anthracycline-based chemotherapy in a predominantly adult population. There is no high-level evidence to guide clinical decision-making regarding the prevention, detection or management of radiation-induced cardiotoxicity.
This paper references
10.1016/S0140-6736(07)61865-0
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu (2007)
10.1016/S1470-2045(06)70940-8
Multidisciplinary teams in cancer care: are they effective in the UK?
A. Fleissig (2006)
10.1111/j.1365-2133.2012.11092.x
Euromelanoma: a dermatology‐led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future
A. Stratigos (2012)
10.1002/14651858.CD005006.pub3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)
10.1038/sj.bjc.6603562
Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review
J. Bryant (2007)
10.1016/j.ctrv.2010.11.001
Cardiovascular effects of systemic cancer treatment.
E. Senkus (2011)
10.1002/14651858.CD006165.pub3
Interventions for latent autoimmune diabetes (LADA) in adults.
S. Brophy (2011)
10.2174/138161210789941847
Recent advances in cancer therapy: an overview.
A. Urruticoechea (2010)
10.1016/J.EJCA.2007.01.040
Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
E. C. van Dalen (2007)
10.1038/sj.bjc.6605382
The National Awareness and Early Diagnosis Initiative in England: assembling the evidence
M. Richards (2009)
10.1002/14651858.CD006647.pub4
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
E. C. van Dalen (2014)
10.1371/journal.pmed.0040078
Epidemiology and Reporting Characteristics of Systematic Reviews
D. Moher (2007)
10.1002/14651858.cd003917.pub2
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2005)
10.1016/j.breast.2012.02.011
Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
Igor Lemos Duarte (2012)
10.1016/S0094-0143(05)70072-0
Chemotherapy for hormone refractory prostate cancer.
D. Smith (1999)
10.1002/14651858.CD008909.pub2
Anthracycline-containing regimens for treatment of follicular lymphoma in adults.
Gilad Itchaki (2013)
10.1002/14651858.CD003917.pub3
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2008)
10.1002/14651858.cd005008.pub2
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
E. C. van Dalen (2006)
10.1186/1471-2288-7-10
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews
B. Shea (2007)
10.1002/14651858.CD008011.pub3
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
D. Cheuk (2016)
10.1016/j.jclinepi.2008.10.009
AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews.
B. Shea (2009)
10.1002/14651858.CD005247.PUB2
Chemotherapy for hormone-refractory prostate cancer.
M. Shelley (2006)
10.1146/annurev-med-070213-054849
Cardiovascular disease in adult survivors of childhood cancer.
S. Lipshultz (2015)
10.1016/J.EJCA.2007.06.012
Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review.
J. Bryant (2007)
10.1634/theoncologist.2008-0120
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Thomas E. Hutson (2008)
10.1093/ANNONC/MDS293
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.
G. Curigliano (2012)
10.1016/S1470-2045(09)70028-2
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England.
B. Rachet (2009)
Australia. 2 Division of Cancer Services, Princess Alexandra Hospital and School of Nursing, Institute of Health and Biomedical Innovation
10.1371/journal.pone.0026946
Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients
Yingyi Qin (2011)
10.1002/14651858.CD003367.PUB2
Antitumour antibiotic containing regimens for metastatic breast cancer.
S. Lord (2004)
10.1002/ijc.28234
Cardiac toxicity in breast cancer patients treated with dual HER2 blockade
A. Valachis (2013)
10.1016/j.pcad.2010.06.005
Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected?
Quinn S. Wells (2010)
10.1002/14651858.cd006647.pub3
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
E. C. van Dalen (2011)
10.1186/1471-2407-7-153
Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
G. Viani (2007)
10.1016/S1470-2045(13)70546-1
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.
R. de Angelis (2014)
Clinical and costeffectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review
J Bryant (2007)
10.1002/14651858.CD004421.PUB2
Taxanes for adjuvant treatment of early breast cancer.
T. Ferguson (2007)
10.1016/j.lpm.2009.02.017
[Anthracycline-induced cardiomyopathy].
G. Roul (2009)
Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
Jp Higgins (2011)
10.1016/j.ejca.2011.03.024
The use of liposomal anthracycline analogues for childhood malignancies: A systematic review.
E. Sieswerda (2011)
10.1002/9781119536604
Cochrane Handbook for Systematic Reviews of Interventions
Michele Tarsilla (2010)
10.1186/1471-2407-10-337
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
L. Smith (2010)
10.1016/j.ctrv.2010.08.007
Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.
Cyrus Chargari (2011)
10.1001/JAMA.295.11.1281
Transition from meeting abstract to full-length journal article for randomized controlled trials.
M. Toma (2006)
10.1016/j.jacc.2009.03.095
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
D. Cardinale (2010)
10.1016/j.ijnurstu.2012.05.007
Two decades of exceptional achievements: does the evidence support nurses to favour Cochrane systematic reviews over other systematic reviews?
R. Chan (2012)
10.1161/CIRCULATIONAHA.111.021774
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.
J. Scott (2011)
10.1200/JCO.2004.02.034
Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review.
L. Roffe (2004)



This paper is referenced by
10.3892/etm.2018.6482
Bioinformatics identification of potential candidate blood indicators for doxorubicin-induced heart failure
Guo-xing Wan (2018)
10.1093/ehjci/jev168
Strain and left ventricular volumes for predicting cardiotoxicity: a life-saving approach in anthracycline cancer treatment?
J. Bergler-Klein (2015)
10.1016/j.vascn.2018.08.004
Integration of cardiac energetics, function and histology from isolated rat hearts perfused with doxorubicin and doxorubicin-ol; a model for use in drug safety evaluations.
Kim A. Henderson (2018)
10.1002/pbc.27308
Role of ACE inhibitors in anthracycline‐induced cardiotoxicity: A randomized, double‐blind, placebo‐controlled trial
V. Gupta (2018)
10.1371/journal.pone.0145418
S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers
U. Eryılmaz (2015)
Chemotherapy-Induced Cardiomyopathy: Clinical Scenarios and Challenges.
Dipti Gupta (2015)
Anthracycline-Induced Cardiotoxicity in Adults
J. Bubalo (2018)
Protective Effects Of Trimetazidine Against Doxorubicin-Induced Cardiotoxicity And Hepatotoxicity In Mice.
Abeera Sikandar (2020)
10.1136/bcr-2018-228149
First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia
Zarir Ahmed (2019)
10.1007/978-3-319-40236-9_7
The Pharmacologist’s Point of View: Mechanisms of Cardiotoxicity
B. Bassani (2017)
10.1111/jcmm.14466
Yellow Wine Polyphenolic Compounds prevents Doxorubicin‐induced cardiotoxicity through activation of the Nrf2 signalling pathway
H. Lin (2019)
10.26355/eurrev_201804_14752
Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer.
M. A. Nicolazzi (2018)
10.3389/fphar.2020.00788
Protective Role of Enalapril in Anthracycline-Induced Cardiotoxicity: A Systematic Review
Yi-li Zhang (2020)
10.3389/fmolb.2019.00077
Integrated Metabolomics-DNA Methylation Analysis Reveals Significant Long-Term Tissue-Dependent Directional Alterations in Aminoacyl-tRNA Biosynthesis in the Left Ventricle of the Heart and Hippocampus Following Proton Irradiation
E. R. Torres (2019)
10.1152/ajpheart.00155.2018
Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Y. Lue (2018)
10.1186/s13293-016-0124-4
Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice
M. K. Grant (2016)
10.1016/j.ccl.2019.07.002
Cardiovascular Toxicities in Pediatric Cancer Survivors.
T. D. Ryan (2019)
Sex diff erences in anthracycline cardiotoxicity
R. Ventura-Clapier (2018)
10.1007/s11864-019-0658-x
Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients
T. D. Ryan (2019)
10.1016/j.critrevonc.2019.05.017
Antineoplastic-related cardiovascular toxicity: A systematic review and meta-analysis in Asia.
Siew Lian Leong (2019)
10.20381/RUOR-21220
Nurses Supporting Cancer Survivors with the Self-Management of Symptoms
Freya Kelly (2017)
10.1007/978-3-319-49256-8_10
Acute Respiratory Failure Before ICU Admission: A Practical Approach
E. Diamantaki (2017)
Documento di consenso ANMCO/AICO/AIOM: Snodi clinico-gestionali in ambito cardioncologico
L. Tarantini (2017)
Tailored exercise as a protective tool in cardio-oncology rehabilitation: a narrative review
D. García-González (2020)
10.2217/fon.15.139
Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers.
N. Akhter (2015)
10.1007/s00204-020-02711-8
GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes
S. Karhu (2020)
10.1177/1078155217697487
The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity
P. L. Chia (2018)
10.1016/J.TACC.2017.03.002
Preoperative cardiac evaluation and anesthetic considerations for cancer patients who underwent chemotherapy
Marco Cascella (2017)
10.4103/2008-7802.184314
Potential Effects of Pomegranate on Lipid Peroxidation and Pro-inflammatory Changes in Daunorubicin-induced Cardiotoxicity in Rats
Hayder M Al-Kuraishy (2016)
10.1097/MD.0000000000004237
Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R
E. Porpaczy (2016)
10.1007/978-3-030-49140-6_30
Late Effects in Children and Adolescents with Osteosarcoma
S. S. Bielack (2021)
10.1097/MD.0000000000005228
Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes
Fangyi Sun (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar